Heidenreich, Regina

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines

Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K. E., Baumhof, P., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., Heidenreich, R., et al. (2017) · npj Vaccines

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 257

A novel, disruptive vaccination technology: Self-adjuvanted RNActive ® vaccines

Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 223

mRNA mediates passive vaccination against infectious agents, toxins, and tumors

Thran, M., Mukherjee, J., Pönisch, M., Fiedler, K., Thess, A., Mui, B. L., Hope, M. J., Tam, Y. K., Horscroft, N., Heidenreich, R., et al. (2017) · EMBO Molecular Medicine

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 166

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

Fotin‐Mleczek, M., Zanzinger, K., Heidenreich, R., Lorenz, C., Thess, A., Duchardt, K. M., & Kallen, K. (2012) · The Journal of Gene Medicine

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 103

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity

Kowalczyk, A., Doener, F., Zanzinger, K., Noth, J., Baumhof, P., Fotin-Mleczek, M., & Heidenreich, R. (2016) · Vaccine

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 101

RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines

Rauch, S., Lutz, J., Kowalczyk, A., Schlake, T., & Heidenreich, R. (2017) · Methods in Molecular Biology

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 57

RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

Doener, F., Hong, H. S., Meyer, I., Tadjalli-Mehr, K., Daehling, A., Heidenreich, R., Koch, S. D., Fotin-Mleczek, M., & Gnad-Vogt, U. (2019) · Vaccine

Rabies epidemiology and controlImmunotherapy and Immune Responses

Cited by 48

Preclinical development of an mRNA-based multiepitope immunotherapeutic for glioblastoma

Lutz, J., Feist, R. K., Sonntag, T., Peguero-Sánchez, E., Wolter, K., Bick, R., Bauer, J., Walz, J. S., & Heidenreich, R. (2025) · Cancer Immunology, Immunotherapy

Immunotherapy and Immune ResponsesCancer Immunotherapy and Biomarkers

Cited by 9